PRJ1-3024 / MingMed Biotech - LARVOL DELTA

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd | Trial completion date: Oct 2024 ➔ Jun 2026 | Completed ➔ Active, not recruiting

Enrollment closed • First-in-human • Trial completion date • Oncology • Solid Tumor

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Completed | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd | Recruiting ➔ Completed | Trial primary completion date: Feb 2024 ➔ Jul 2024

Metastases • Trial completion • Trial primary completion date • Oncology • Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=267 | Recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd | Trial completion date: Mar 2025 ➔ Nov 2027 | Trial primary completion date: Nov 2024 ➔ May 2027

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd

Metastases • New P1/2 trial • Melanoma • Oncology • Solid Tumor

A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors. (ASCO 2024) - P1/2 | "PRJ1-3024 is shown to be well tolerated in Chinese advanced solid tumor patients. Further safety and efficacy results would be presented at the conference."

Clinical • Metastases • P1/2 data • PK/PD data • Acute Kidney Injury • Anorexia • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Myocardial Ischemia • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • CD4 • CD8 • LCP2

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=267 | Recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=267 | Not yet recruiting | Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd

New P1/2 trial • Oncology • Solid Tumor

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=46; Not yet recruiting; Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd

Clinical • New P1 trial • Oncology • Solid Tumor

MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102 (PRNewswire) - "MingMed Biotechnology...announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a HPK1 small-molecule inhibitor for cancer immunotherapy."

IND • Oncology